RARA and acute promyelocytic leukemia: In relapsed/refractory acute promyelocytic leukemia, resistance is frequently attributable to mutations within PML–RARα, most notably those affecting the PML zinc-finger domain that impair ATO binding, or to mutations within the ATRA-binding pocket.[18] Continued use of ATRA/ATO therefore offers limited efficacy in these patients.